Effective gmp-compliant point of care manufacturing of anticd19 chimeric antigen receptor t cells for non hodgkin lymphoma patients using the clinimacs prodigy®

Kleinsorge-Block, Sarah; Payne-Schiavone, J.; Zamborsky, Kayla; Turney, T.L.; Reese, Jane; Wald, David N.; Otegbeye, Folashade; Lima, Marcos de; Caimi, Paolo

doi:10.1016/j.jcyt.2020.03.261

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other integrated manufacturing platforms, such as the CliniMACS Prodigy System, are fully enclosed and designed to incorporate T-cell selection, activation, transduction, expansion and formulation, enabling a higher degree of automation, supporting continuous cell culture, and largely decreasing interpersonal operator variability. Phase I clinical trials conducted with CD19 CAR T cells manufactured in the CliniMACS Prodigy have generated encouraging clinical responses which have the potential to enable the concept of point-of-care manufacturing [122][123][124][125][126]. Another newly available integrated end-to-end cell manufacturing solution is the Cocoon platform, which is currently being investigated in a clinical trial at the Sheba Medical Center, Israel [127] (NCT02772198).…”

Section: T-cell Expansionmentioning

confidence: 99%

CAR T cells: Building on the CD19 paradigm

et al. 2021

View full text Add to dashboard Cite

Spearheaded by the therapeutic use of chimeric antigen receptors (CARs) targeting CD19, synthetic immunology has entered the clinical arena. CARs are recombinant receptors for antigen that engage cell surface molecules through the variable region of an antibody and signal through arrayed T-cell activating and costimulatory domains. CARs allow redirection of T-cell cytotoxicity against any antigen of choice, independent of MHC expression. Patient T cells engineered to express CARs specific for CD19 have yielded remarkable outcomes in subjects with relapsed/refractory B-cell malignancies, setting off unprecedented interest in T-cell engineering and cell-based cancer immunotherapy. In this review, we present the challenges to extend the use of CAR T cells to solid tumors and other pathologies. We further highlight progress in CAR design, cell manufacturing, and genome editing, which in aggregate hold the promise of generating safer and more effective genetically instructed immunity. Novel engineered cell types, including innate T-cell types, natural killer (NK) cells, macrophages, and induced pluripotent stem cell-derived immune cells, are on the horizon, as are applications of CAR T cells to treat autoimmunity, severe infections, and senescence-associated pathologies.

show abstract